AR114666A1 - Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer - Google Patents

Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer

Info

Publication number
AR114666A1
AR114666A1 ARP190100547A ARP190100547A AR114666A1 AR 114666 A1 AR114666 A1 AR 114666A1 AR P190100547 A ARP190100547 A AR P190100547A AR P190100547 A ARP190100547 A AR P190100547A AR 114666 A1 AR114666 A1 AR 114666A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
ring
hydrogen
membered
Prior art date
Application number
ARP190100547A
Other languages
English (en)
Spanish (es)
Inventor
William R Baker
Original Assignee
Celgene Int Ii Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Int Ii Sarl filed Critical Celgene Int Ii Sarl
Publication of AR114666A1 publication Critical patent/AR114666A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ARP190100547A 2018-03-07 2019-03-06 Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer AR114666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
AR114666A1 true AR114666A1 (es) 2020-09-30

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100547A AR114666A1 (es) 2018-03-07 2019-03-06 Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer

Country Status (11)

Country Link
US (1) US11639332B2 (https=)
EP (1) EP3762365B1 (https=)
JP (1) JP7396991B2 (https=)
AR (1) AR114666A1 (https=)
AU (1) AU2019229583B2 (https=)
CA (1) CA3093196A1 (https=)
ES (1) ES2987705T3 (https=)
MA (1) MA52266A (https=)
MX (1) MX2020009288A (https=)
TW (1) TW202000646A (https=)
WO (1) WO2019170750A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JPWO2002001667A1 (ja) * 2000-06-29 2004-01-08 日本化薬株式会社 色素増感光電変換素子
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
CA2718601A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
MX347928B (es) 2011-01-10 2017-05-19 Celgene Corp Derivados de fenetilsulfona isoindolina y su uso.

Also Published As

Publication number Publication date
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
CA3093196A1 (en) 2019-09-12
EP3762365A1 (en) 2021-01-13
TW202000646A (zh) 2020-01-01
JP7396991B2 (ja) 2023-12-12
ES2987705T3 (es) 2024-11-15
AU2019229583B2 (en) 2024-06-13
JP2021517134A (ja) 2021-07-15
US20200392082A1 (en) 2020-12-17
US11639332B2 (en) 2023-05-02
WO2019170750A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365B1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR088449A1 (es) Benzilindazoles sustituidos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure